Organisation
Department of Basic and Applied Medical Sciences
Department
Current researchers
61 - 70 of 71 results
- Lies Vancraeynest (Member)
- Nicolas Vandenbussche (Member)
- Jolien Vander Cruyssen (Member)
- Robert Vander Stichele (Member)
- Caroline Vanpeteghem (Member)
- Maxim Vanwulpen (Member)
- Tijl Vermassen (Member)
- Katja Witschas (Member)
- Patrick Wouters (Member)
- Piet Wyffels (Member)
Projects
61 - 70 of 81
- NaV1.9 regulation of itchFrom15 Apr 2019 → TodayFunding: BOF - projects
- Tenure track professorship in physiology and cell physiologyFrom1 Oct 2018 → 30 Sep 2023Funding: BOF - tenure track
- Controlled delivery of connexin43 mimetic peptide by nanocontainers for therapy of systemic inflammationFrom1 Oct 2018 → 31 Jul 2023Funding: BOF - Doctoral projects
- Combined single-channel electrophysiology and fluorescence microscopy for fundamental studies of ion channel functionFrom1 Jun 2018 → 31 May 2020Funding: BOF - Other initiatives
- A pilot study of the OptiMEDs intervention: A complex intervention for multidisciplinary review (including nurses, pharmacists, and physicians) in nursing homes, with ICT-support for the evaluation of the appropriateness of prescribing and for side-effectFrom1 Jun 2018 → 31 Dec 2019Funding: Ministery of Social Affairs, Public Health and Environment
- Basic investigations on the role of connexin hemichannels as an arrhythmogenic substrate in ventricular arrhythmiaFrom1 Jan 2018 → 31 Dec 2021Funding: FWO research project (including WEAVE projects)
- Centre for Advanced Light MicroscopyFrom1 Aug 2017 → 30 Nov 2022Funding: BOF - Doctoral projects
- Exploring the role of astroglial Cx43 hemichannels as therapeutic targets in stroke.From1 Jan 2017 → 31 Dec 2018Funding: Foundations, funds and other with scientific goal
- Uncovering liver macrophage subsets and the role of macrophage prolyl hydroxylases in the pathogenesis of non-alcoholic steatohepatitis and associated liver cancer From1 Oct 2016 → 30 Sep 2019Funding: BOF - Doctoral projects
- the spreading mechanisms and responsible messengers of the radiation induced bystander effectFrom1 Oct 2015 → 30 Sep 2019Funding: FWO fellowships
Publications
1 - 10 of 1655
- Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma(2016)
Authors: Tijl Vermassen, M. Van de Walle, Sylvie Rottey
Pages: 12 - 18 - REACT expanded-access program in patients with metastatic renal cell carcinoma : real-world data from a European subanalysis(2015)
Authors: S Bracarda, Sylvie Rottey, A Bahl, C Eichelberg, B Mellado, L Mangel, A Cattaneo, A Panneerselvam, V Grunwald
Pages: 2893 - 2903 - Mobile health technology captures 'in-house' data on the outside : an assessment with pharmacological intervention(2019)Volume: 105
Authors: G Bhatia, Q Huang, T Crumley, C Walters, L Cluckers, I Heirman, L Mixson, Sylvie Rottey, M Cantor, C Benko, et al.
Pages: S73 - S73 - Glycosylation of urinary prostate proteins and its potential diagnostic applications(2017)
Authors: Tijl Vermassen
Pages: 126 - 128 - Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer(2020)Volume: 8
Authors: Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, et al.
Pages: A207 - A208 - Cytoreductive nephrectomy and exposure to sunitinib : a post hoc analysis of the immediate surgery or surgery after sunitinib malate in treating patients with metastatic kidney cancer (SURTIME) trial(2022)
Authors: Yasmin AbuU+2010Ghanem, Johannes V. Thienen, Christian Blank, Maureen J. B. Aarts, Michael Jewett, Igle Jan Jong, JeanU+2010Baptiste Lattouf, Harm H. E. Melick, Lori Wood, Peter Mulders, et al.
Pages: 68 - 75 - Nephrotoxicity of anticancer drugs: an underestimated problem?(2011)
Authors: VIBEKE KRUSE, Sylvie Rottey
Pages: 337 - 345 - Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial(2013)
Authors: Jan B Vermorken, Jan Stoelmacher-Williams, Irina Davidenko, Lisa Licitra, Eric Winquist, Cristian Villanueva, Paolo Foa, Sylvie Rottey, Krzysztof Skladowski, Makoto Tahara, et al.
Pages: 697 - 710 - A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors(2020)Volume: 80
Authors: Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ani Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, et al.
Number of pages: 1 - Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial(2019)
Authors: Axel Bex, Peter Mulders, Michael Jewett, John Wagstaff, Johannes V van Thienen, Christian U Blank, Roland van Velthoven, Maria del Pilar Laguna, Lori Wood, Harm HE van Melick, et al.
Pages: 164 - 170